Minovia Therapeutics Ltd.
๐ฎ๐ฑIsrael
- Country
- ๐ฎ๐ฑIsrael
- Ownership
- Holding
- Established
- 2011-07-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.minoviatx.com
Collection of Blood and Skin Samples From Patients With Primary Mitochondrial Diseases and Healthy Volunteers
Recruiting
- Conditions
- Primary Mitochondrial Diseases
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Minovia Therapeutics Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06474104
- Locations
- ๐ฎ๐ฑ
Sheba Medical Center - Tel Ashomer, Ramat Gan, Israel
A Study to Evaluate the MNV-201 in Patients with Low Risk MDS
Phase 1
Recruiting
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Biological: MNV-201 (Autologous CD34+ Cells Enriched with allogenic Placenta Derived Mitochondria)
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Minovia Therapeutics Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT06465160
- Locations
- ๐ฎ๐ฑ
Shaare Zedek Medical Center, Jerusalem, Israel
Collection of Samples of Bone Marrow Aspiration From Patients With Myelodysplastic Syndrome
Recruiting
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Procedure: Blood test
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Minovia Therapeutics Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06144515
- Locations
- ๐ฎ๐ฑ
Shaare Zedek Medical Center, Jerusalem, Israel
Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-201 in Pediatric Patients With Pearson Syndrome
Phase 1
Recruiting
- Conditions
- Mitochondrial DiseasesPearson Syndrome
- Interventions
- Biological: MNV-201
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Minovia Therapeutics Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT06017869
- Locations
- ๐ฎ๐ฑ
Sheba Medical Center, Ramat Gan, Israel
A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion
Phase 1
- Conditions
- Primary Mitochondrial Diseases
- Interventions
- Procedure: Bone Marrow mobilizationProcedure: ApheresisBiological: MNV-BM-PLC infusion
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- Minovia Therapeutics Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT04548843
- Locations
- ๐ฎ๐ฑ
Sheba Medical Center - Tel Ashomer, Ramat Gan, Israel
Collection of Placenta for Mitochondria Isolation
Recruiting
- Conditions
- Pregnancy Related
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2020-06-22
- Lead Sponsor
- Minovia Therapeutics Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03762512
- Locations
- ๐ฎ๐ฑ
Sheba Medical Center Hospital- Tel Hashomer, Ramat Gan, Israel
A Study to Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-BM-BLD in Pediatric Patients With Pearson Syndrome
Phase 1
Completed
- Conditions
- Mitochondrial DiseasesPearson Syndrome
- Interventions
- Biological: CD34+ cells enriched with MNV-BLD
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- Minovia Therapeutics Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT03384420
- Locations
- ๐ฎ๐ฑ
Sheba Medical Center Hospital- Tel Hashomer, Ramat Gan, Israel
ยฉ Copyright 2025. All Rights Reserved by MedPath